Mylan Laboratories Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Mylan Laboratories Ltd (Mylan), a subsidiary of Mylan NV is a pharmaceutical company that manufactures and supplies API products. The company offers HIV care products for the treatment of HIV/AIDS. It provides womens care products for therapies such as hormone replacement therapy, infertility and maintenance of early pregnancy. Mylan offers infertility care products which include follicle stimulating hormone, human menopausal gonadotropins and human chorionic gonadotropins. The companys onco care division provides cancer-related cytotoxic and targeted therapy products. Its critical care division offers anti-fungal, antibiotic and anticoagulant therapies. The company operates through its manufacturing units in India and China. Mylan is headquartered in Hyderabad, Telangana, India.

Mylan Laboratories Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 10
Partnerships 11
Matrix Labs Plans Co-Marketing Agreement For 100 Products 11
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 12
Licensing Agreements 13
Gilead Sciences Expands Licensing Agreement with Mylan Labs 13
Gilead Sciences Expands Licensing Agreement with Mylan Labs 14
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 15
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 16
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 17
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 19
Mylan Laboratories Ltd - Key Competitors 21
Mylan Laboratories Ltd - Key Employees 22
Mylan Laboratories Ltd - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 23
Recent Developments 24
Legal and Regulatory 24
May 29, 2017: Phosphagenic - Mylan Arbitration Update expert report on quantum of damages claimed filed 24
Jan 06, 2016: Phosphagenics Initiates Arbitration against Mylan 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List Of Tables

List of Tables
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Mylan Laboratories Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Mylan Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 10
Matrix Labs Plans Co-Marketing Agreement For 100 Products 11
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 12
Gilead Sciences Expands Licensing Agreement with Mylan Labs 13
Gilead Sciences Expands Licensing Agreement with Mylan Labs 14
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 15
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 16
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 17
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 19
Mylan Laboratories Ltd, Key Competitors 21
Mylan Laboratories Ltd, Key Employees 22
Mylan Laboratories Ltd, Subsidiaries 23
Mylan Laboratories Ltd, Joint Venture 23

Mylan Full Year Operating Financial

Mylan 2023 Full Year Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Pharmaceutical Industry This report is part of the Competitive

USD 750 View Report

Mylan 2023 Third Quarter Operating and Financial Review

Mylan 2023 Third Quarter Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Pharmaceutical Industry This report is part of the Competitive

USD 750 View Report

Proteomics International Laboratories Ltd (PIQ) - Product Pipeline Analysis, 2020 Update

Proteomics International Laboratories Ltd (Proteomics) operates as a medical technology company that discovers new biopharmaceutical drugs. The company harnesses its proprietary proteomics-based technology platform to work in three integrated areas;

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available